Colin F Spraggs

Summary

Affiliation: GlaxoSmithKline Research and Development
Country: USA

Publications

  1. ncbi Lapatinib-induced liver injury characterized by class II HLA and Gilbert's syndrome genotypes
    C F Spraggs
    Genetics Department, GlaxoSmithKline Research and Development, Stevenage, UK
    Clin Pharmacol Ther 91:647-52. 2012
  2. ncbi Genetic variants in the epithelial sodium channel associate with oedema in type 2 diabetic patients receiving the peroxisome proliferator-activated receptor gamma agonist farglitazar
    Colin Spraggs
    Pharmacogenetics, GlaxoSmithKline Research and Development, Harlow, Essex, UK
    Pharmacogenet Genomics 17:1065-76. 2007
  3. ncbi HLA-DQA1*02:01 is a major risk factor for lapatinib-induced hepatotoxicity in women with advanced breast cancer
    Colin F Spraggs
    GlaxoSmithKline Research and Development, Genetics Division, Medicines Development Centre, Gunnels Wood Road, Stevenage, Hertfordshire, SG1 2NF, United Kingdom
    J Clin Oncol 29:667-73. 2011
  4. ncbi Pazopanib efficacy in renal cell carcinoma: evidence for predictive genetic markers in angiogenesis-related and exposure-related genes
    Chun Fang Xu
    GlaxoSmithKline Medicines Research Centre, Rm 1S101, Gunnels Wood Rd, Stevenage, Hertfordshire, UK
    J Clin Oncol 29:2557-64. 2011
  5. ncbi Association of the hemochromatosis gene with pazopanib-induced transaminase elevation in renal cell carcinoma
    Chun Fang Xu
    GlaxoSmithKline Research and Development, Genetics Division, Stevenage, UK
    J Hepatol 54:1237-43. 2011
  6. ncbi Pharmacogenetics and obesity: common gene variants influence weight loss response of the norepinephrine/dopamine transporter inhibitor GW320659 in obese subjects
    Colin F Spraggs
    Genetics Research, GlaxoSmithKline Research and Development, Medicines Research Centre, Stevenage, UK
    Pharmacogenet Genomics 15:883-9. 2005

Detail Information

Publications6

  1. ncbi Lapatinib-induced liver injury characterized by class II HLA and Gilbert's syndrome genotypes
    C F Spraggs
    Genetics Department, GlaxoSmithKline Research and Development, Stevenage, UK
    Clin Pharmacol Ther 91:647-52. 2012
    ....
  2. ncbi Genetic variants in the epithelial sodium channel associate with oedema in type 2 diabetic patients receiving the peroxisome proliferator-activated receptor gamma agonist farglitazar
    Colin Spraggs
    Pharmacogenetics, GlaxoSmithKline Research and Development, Harlow, Essex, UK
    Pharmacogenet Genomics 17:1065-76. 2007
    ....
  3. ncbi HLA-DQA1*02:01 is a major risk factor for lapatinib-induced hepatotoxicity in women with advanced breast cancer
    Colin F Spraggs
    GlaxoSmithKline Research and Development, Genetics Division, Medicines Development Centre, Gunnels Wood Road, Stevenage, Hertfordshire, SG1 2NF, United Kingdom
    J Clin Oncol 29:667-73. 2011
    ..This study sought to identify gene variants associated with lapatinib-induced ALT elevation and hepatobiliary AEs...
  4. ncbi Pazopanib efficacy in renal cell carcinoma: evidence for predictive genetic markers in angiogenesis-related and exposure-related genes
    Chun Fang Xu
    GlaxoSmithKline Medicines Research Centre, Rm 1S101, Gunnels Wood Rd, Stevenage, Hertfordshire, UK
    J Clin Oncol 29:2557-64. 2011
    ..We tested the hypothesis that this variability is partially dependent on germline genetic variants that may affect pazopanib exposure or angiogenesis pathways...
  5. ncbi Association of the hemochromatosis gene with pazopanib-induced transaminase elevation in renal cell carcinoma
    Chun Fang Xu
    GlaxoSmithKline Research and Development, Genetics Division, Stevenage, UK
    J Hepatol 54:1237-43. 2011
    ..However, transaminase elevations have commonly been observed. This 2-stage study sought to identify genetic determinants of alanine transaminase (ALT) elevations in pazopanib-treated white patients with RCC...
  6. ncbi Pharmacogenetics and obesity: common gene variants influence weight loss response of the norepinephrine/dopamine transporter inhibitor GW320659 in obese subjects
    Colin F Spraggs
    Genetics Research, GlaxoSmithKline Research and Development, Medicines Research Centre, Stevenage, UK
    Pharmacogenet Genomics 15:883-9. 2005
    ....